Abstract: Peripheral vascular disease is a widespread clinical problem, accounting for more than one million vascular graft surgeries each year in the United States. To date, attempts to develop a ...
Blood vessel replacements (vascular grafts) are used today for hemodialysis blood access, trauma repair and cardiovascular reconstruction The first synthetic vascular grafts (blood vessel replacements ...
MedPage Today on MSN
Stent Graft for Ruptured AAA; Biodegradable PFO Occluder; 24/7 Vascular Service Sued
The Medtronic Endurant stent graft system got FDA approval to remove a warning against use for ruptured abdominal aortic ...
MADISON — Scientists at the Wisconsin National Primate Research Center (WNPRC) and the Morgridge Institute for Research at the University of Wisconsin–Madison have been at the forefront of stem cell ...
Xcellerex will leverage its XDR bioreactors and FlexFactory platform to allow future scale-up. Xcellerex and Humacyte signed a collaboration agreement under which Xcellerex will develop a single-use ...
A team of researchers at Cornell University has developed a new biodegradable vascular graft that could transform the treatment of cardiovascular disease, the leading cause of death worldwide. Anova ...
Applying a molecule derived from seaweed to synthetic vascular grafts improves in situ endothelialization and could lead to better bypass surgery outcomes. A recent paper from scientists at the ...
Company also elevates Jeff O’Donnell, Sr. to executive chairman and moves polymer processing in-house to new local manufacturing facility as it reaches critical inflection point PITTSBURGH--(BUSINESS ...
In a study published in the journal Burns & Trauma, researchers from Shanghai Jiao Tong University and Donghua University developed a new type of vascular graft using 3D printing and electrospinning.
In a recent study published in Advanced Materials, a team of researchers developed a novel small-diameter biodegradable vascular graft that aids the formation of elastin-containing structures in the ...
SAN FRANCISCO (MarketWatch) -- Angiotech Pharmaceuticals Inc. said Thursday that it has agreed to pay $14 million cash for Edwards Lifesciences Corp.'s Lifespan ePTFE vascular graft business. The deal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback